(Q45862335)

17 December 2017

title

Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration (English)

1 reference

17 December 2017

1 reference

Parks R

1

1 reference

17 December 2017

Evelegh C

series ordinal

2

1 reference

17 December 2017

Graham F

series ordinal

3

1 reference

17 December 2017

publication date

1 September 1999

1 reference

17 December 2017

published in

Gene Therapy

1 reference

17 December 2017

volume

6

1 reference

17 December 2017

issue

9

1 reference

17 December 2017

page(s)

1565-1573

1 reference

17 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.gt.3300995

exact match

0 references

cites work

Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

Transient expression of genes transferred in vivo into heart using first-generation adenoviral vectors: role of the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

Pulmonary inflammation induced by incomplete or inactivated adenoviral particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

Systematic analysis of repeated gene delivery into animal lungs with a recombinant adenovirus vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

Heterologous expression of adenovirus E3-gp19K in an E1a-deleted adenovirus vector inhibits MHC I expression in vitro, but does not prolong transgene expression in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

Transfer of the CFTR Gene to the Lung of Nonhuman Primates with E1-Deleted, E2a-Defective Recombinant Adenoviruses: A Preclinical Toxicology Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

Persistent transgene expression in mouse liver following in vivo gene transfer with a delta E1/delta E4 adenovirus vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

Persistence in muscle of an adenoviral vector that lacks all viral genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

Anti-T cell receptor monoclonal antibody prolongs transgene expression following adenovirus-mediated in vivo gene transfer to mouse synovium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

Macrophage depletion increases the safety, efficacy and persistence of adenovirus-mediated gene transfer in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

Antibody to CD40 ligand inhibits both humoral and cellular immune responses to adenoviral vectors and facilitates repeated administration to mouse airway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

Anti-T cell receptor antibody prolongs transgene expression and reduces lung inflammation after adenovirus-mediated gene transfer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

Extensive cross-reactivity of adenovirus-specific cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

Production and characterization of human 293 cell lines expressing the site-specific recombinase Cre.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

Characteristics of a human cell line transformed by DNA from human adenovirus type 5

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

Human adenovirus vectors for gene transfer into mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

7 January 2021

Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

7 January 2021

Expression of gp19K increases the persistence of transgene expression from an adenovirus vector in the mouse lung and liver

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

7 January 2021

Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

7 January 2021

Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

7 January 2021

Use of transient CD4 lymphocyte depletion to prolong transgene expression of E1-deleted adenoviral vectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

7 January 2021

Transient immunosuppression with deoxyspergualin improves longevity of transgene expression and ability to readminister adenoviral vector to the mouse lung

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

7 January 2021

Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

7 January 2021

"Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

7 January 2021

Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

7 January 2021

Circumvention of immunity to the adenovirus major coat protein hexon.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

7 January 2021

Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

7 January 2021

Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

7 January 2021

Effects of stuffer DNA on transgene expression from helper-dependent adenovirus vectors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3300995

7 January 2021

Identifiers

DOI

10.1038/SJ.GT.3300995

1 reference

17 December 2017

Dimensions Publication ID

1015936596

0 references

Fatcat ID

release_ht2lhxcxurd7raktktbd353bee

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ht2lhxcxurd7raktktbd353bee

24 November 2022

mapped directly with Wikidata item

PubMed ID

10490766

1 reference

17 December 2017